Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FATEN NUREDDIN ABERRA

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1225042989
CMS profile
939019
Location
PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$770.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $770.00 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $770.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FATEN NUREDDIN ABERRA

NPI 1225042989 · CMS profile ID 939019

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

PHILADELPHIA, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1225042989?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FATEN NUREDDIN ABERRA, NPI 1225042989, CMS profile ID 939019. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1225042989?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). FATEN NUREDDIN ABERRA, NPI 1225042989, CMS profile ID 939019. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1225042989?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
FATEN NUREDDIN ABERRA, NPI 1225042989, CMS profile ID 939019, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1225042989?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $770.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $770.0011/22/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932680199 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,024.58 9
PY2022 $770.00 1
PY2023 $7,689.10 9
PY2024 $7,422.93 5

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,270.00 2
PY2025 Principal investigator $62,718.95 19
PY2024 Principal investigator $107,749.13 22
PY2023 Principal investigator $225,880.11 46
PY2022 Principal investigator $294,090.59 48
PY2021 Principal investigator $91,356.02 29
PY2020 Principal investigator $66,148.53 23
PY2019 Principal investigator $40,332.90 9

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

48 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,741.83 12/15/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890370093
Principal investigator 1 ABBVIE INC. $1,383.75 12/13/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 889766947
Principal investigator 1 ABBVIE INC. $41,570.65 12/08/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohnx27s Disease No dispute reported 06/30/2026 890370091
Principal investigator 1 ABBVIE INC. $4,000.00 12/01/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 889766933
Principal investigator 1 ABBVIE INC. $17,046.15 12/01/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohnx27s Disease No dispute reported 06/30/2026 890369365
Principal investigator 1 PFIZER INC. $2,006.10 12/01/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949769315
Principal investigator 1 PFIZER INC. $1,475.55 11/10/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949783175
Principal investigator 1 ABBVIE INC. $11,779.75 11/09/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890368405
Principal investigator 1 ABBVIE INC. $27,673.19 11/09/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohnx27s Disease No dispute reported 06/30/2026 890368457
Principal investigator 1 ABBVIE INC. $3,271.50 10/13/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohnx27s Disease No dispute reported 06/30/2026 890368459
Principal investigator 1 ABBVIE INC. $3,181.71 10/11/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohnx27s Disease No dispute reported 06/30/2026 890368403
Principal investigator 1 ABBVIE INC. $4,000.00 10/06/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 889766873
Principal investigator 1 ABBVIE INC. $2,237.00 10/06/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 889766875
Principal investigator 1 ABBVIE INC. $10,894.05 10/06/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 889766877
Principal investigator 1 ABBVIE INC. $2,973.36 10/06/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890368331
Principal investigator 1 ABBVIE INC. $6,969.10 10/06/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohnx27s Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy No dispute reported 06/30/2026 890368455
Principal investigator 1 PFIZER INC. $4,293.00 09/23/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949798941
Principal investigator 1 ABBVIE INC. $1,453.95 09/08/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 889766863
Principal investigator 1 ABBVIE INC. $835.30 09/08/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890366077
Principal investigator 1 ABBVIE INC. $7,803.22 09/08/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohnx27s Disease No dispute reported 06/30/2026 890366081
Principal investigator 1 ABBVIE INC. $4,250.00 09/08/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Participants With Moderately to Severely Active Crohnx27s Disease Who Have Inadequately Responded to or Are Intolerant to Conventional andx2For Biologic Therapies No dispute reported 06/30/2026 890367311
Principal investigator 1 ABBVIE INC. $4,350.00 09/05/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohnx27s Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy No dispute reported 06/30/2026 890367309
Principal investigator 1 PFIZER INC. $2,301.75 08/23/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949800869
Principal investigator 1 ABBVIE INC. $1,558.23 08/11/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890366079
Principal investigator 1 ABBVIE INC. $7,810.25 08/11/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohnx27s Disease No dispute reported 06/30/2026 890366083
Principal investigator 1 PFIZER INC. $1,771.20 08/11/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949801797
Principal investigator 1 ABBVIE INC. $1,694.95 08/04/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Participants With Moderately to Severely Active Crohnx27s Disease Who Have Inadequately Responded to or Are Intolerant to Conventional andx2For Biologic Therapies No dispute reported 06/30/2026 890367313
Principal investigator 1 ABBVIE INC. $28,108.00 08/02/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohnx27s Disease No dispute reported 06/30/2026 890366085
Principal investigator 1 ABBVIE INC. $1,800.90 07/20/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Participants With Moderately to Severely Active Crohnx27s Disease Who Have Inadequately Responded to or Are Intolerant to Conventional andx2For Biologic Therapies No dispute reported 06/30/2026 890365041
Principal investigator 1 ABBVIE INC. $5,250.00 07/20/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Participants With Moderately to Severely Active Crohnx27s Disease Who Have Inadequately Responded to or Are Intolerant to Conventional andx2For Biologic Therapies No dispute reported 06/30/2026 890365043
Principal investigator 1 ABBVIE INC. $11,453.05 07/12/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890365045
Principal investigator 1 ABBVIE INC. $1,190.70 06/29/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 889766811
Principal investigator 1 ABBVIE INC. $7,151.75 06/28/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 889766809
Principal investigator 1 PFIZER INC. $1,771.20 06/25/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949811211
Principal investigator 1 ABBVIE INC. $2,081.00 06/23/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 889766805
Principal investigator 1 PFIZER INC. $1,879.20 05/25/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949754101
Principal investigator 1 ABBVIE INC. $13,363.95 05/12/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890363323
Principal investigator 1 PFIZER INC. $1,771.20 05/06/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949754107
Principal investigator 1 ABBVIE INC. $7,672.10 05/02/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 889766781
Principal investigator 1 PFIZER INC. $2,095.20 04/08/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949815901
Principal investigator 1 ABBVIE INC. $11,524.60 04/07/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890362309
Principal investigator 1 ABBVIE INC. $2,381.40 03/29/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis No dispute reported 06/30/2026 889766767
Principal investigator 1 ABBVIE INC. $4,024.66 03/10/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohnx27s Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 890361125
Principal investigator 1 PFIZER INC. $1,771.20 03/04/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949823475
Principal investigator 1 ABBVIE INC. $1,741.83 02/16/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 889766745
Principal investigator 1 PFIZER INC. $1,879.20 02/12/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949823587
Principal investigator 1 ABBVIE INC. $3,082.71 01/12/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohns Disease Who Completed the Studies M14-431 or M14-433 No dispute reported 06/30/2026 889766731
Principal investigator 1 PFIZER INC. $1,771.20 01/11/2022 Covered Recipient Teaching Hospital
HOSPITAL OF THE UNIV OF PENNA
A PHASE 2B MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED DOSERANGING STUDY TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF PF06480605 IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS No dispute reported 06/30/2026 949820233